Highlights Evofem Biosciences, Inc.

Equities

EVFM

US30048L3024

Delayed OTC Markets Other stock markets 20:47:35 10/05/2024 BST			5-day change	1st Jan Change
0.014 ^USD	-11.95%		+16.67%	-78.12%

03-27	Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-27	Evofem Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-27	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Evofem Biosciences, Inc. Provides Sales Guidance for the Third Quarter of 2023	24/10/23	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	17/08/23	DJ
Evofem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/06/23	CI
Evofem Biosciences, Inc. Receives Paragraph IV Certification Notice Letter from Padagis Israel Pharmaceuticals Ltd	05/05/23	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/04/23	CI
Evofem Biosciences, Inc.'s Phexxi Contraceptive Gel Added to SimpleHealth Product Offering	28/02/23	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	06/01/23	CI
Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women	12/10/22	CI
Evofem Biosciences Announces Approval of Phexxi in Nigeria	06/10/22	CI
Evofem Biosciences, Inc. Announces Issuance of U.S. Patent Covering Phexxi Composition of Matter	23/09/22	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Evofem Biosciences, Inc. Affirms 2022 Guidance	04/08/22	CI
Evofem Biosciences, Inc. Announces Completion of Last Subject Last Visit in Registrational Phase 3 Evoguard Trial Evaluating Phexxi for the Prevention of Chlamydia and Gonorrhea in Women	01/08/22	CI
Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling	25/07/22	CI
U.S. abortion ruling ignites retail interest in women contraceptive makers - Vanda	01/07/22	RE
Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent from United States Patent and Trademark Office	30/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Evofem Biosciences, Inc.

Equities

EVFM

US30048L3024

Highlights

Filters